Latest Nuchev (ASX:NUC) News

Nuchev Limited (ASX: NUC) has secured a final Shanghai arbitration award requiring Nouvlait to pay about RMB9.1 million, including repayment of a disputed advance, losses and interest. The award is legally effective, but Nuchev expects court enforcement may be needed and has not yet received any money.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

Nuchev Limited has transitioned from an agency to a distribution model with H&S Global, aiming to enhance margins and scale growth across key wellness brands.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

Nuchev Limited has locked in a $2 million unsecured working capital facility from major shareholders, aiming to fuel its expansion and push towards profitability in the near term.

Nuchev Limited reported a strong FY25 with revenue doubling to $22.9 million, driven by growth in Oli6® Nutritionals and the integration of bWellness Practitioner channel. Adjusted EBITDA loss narrowed significantly amid improved margins and cost control.

Nuchev Limited reported a remarkable FY25 with revenue doubling to $22.9 million, driven by strong growth in Oli6® Nutritional sales and the acquisition of bWellness. The company improved margins, reduced losses, and expanded into new international markets including Vietnam.

H&S Group has exercised performance options to increase its stake in Nuchev Limited to 48.62%, injecting $1.9 million and enhancing Nuchev’s financial flexibility for growth.